AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 31 min read$GEHC

Tax withholding on RSUs trims GE HealthCare (GEHC) CTO stake

GE HealthCare (GEHC) CTO Taha Kass-Hout had 2,940 shares withheld on September 1, 2026 to cover tax obligations from vested restricted stock units. The shares were withheld at $71.23 each, totaling $209,000 in value. No 10b5-1 trading plan was involved.

Original reporting
stocktitan.net
Published Sep 3, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 12:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GEHC
Neutral
high confidence
Mentioned
$GEHC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$GEHCNeutralLow
01

Why it matters

The filing provides transparency but offers little actionable insight for traders.

02

Market read

Limited to insider monitoring; no broader market impact.

03

What to watch

Potential future RSU vesting schedules could increase withholding amounts, affecting insider dilution over time.

Relevance 4/10Novelty 4/10Timing: Sep 1, 2026 (tax withholding filing date)

Background

Form 4 disclosures report insider transactions. Tax withholding of RSU shares is a routine compliance action.

Company-level read

Ticker impact

$GEHCNeutralHigh confidence
Context

CTO Taha Kass-Hout had 2,940 shares withheld on Sep 1, 2026 to satisfy tax obligations from RSU vesting.

Expected impact

minimal, likely negligible effect on share price

Evidence & confidence

The withholding amount (~$209k) is small relative to market cap and does not signal a change in insider sentiment.

Market effects

Sector

None; the filing is specific to GE HealthCare and does not affect the broader health‑care sector.

Regional

None; limited to GEHC investors.

Global

None

Counterpoint

What could challenge this read

Even small insider withholdings can hint at upcoming compensation changes; monitor future filings for trends.

Key entities

  • Company
    GE HealthCare Technologies Inc.

    US‑listed health‑care equipment and services provider.

  • Executive
    Taha Kass‑Hout

    Chief Technology Officer of GEHC.

Read at source← All news

Related articles

SEP 17
$GEHCMedAI 8/10

GE HealthCare stock maintained at Buy by BTIG on imaging tech

BTIG maintained a Buy rating and $79 price target for GE HealthCare (GEHC) after positive feedback on its new photon-counting CT system. GEHC stock is down 22% YTD but is considered undervalued. The company reported Q2 revenue of $5.295B, beating estimates, and raised its price target to $85. GEHC's backlog reached $23.9B, indicating strong demand.

investing.com2 min
SEP 17
$GEHCMedAI 8/10

GE HealthCare (GEHC) Reportedly Eyes $1B Sofie Deal. What Would Ownership Add?

GE HealthCare (GEHC) is reportedly in talks to acquire Sofie Biosciences for $1B. Sofie holds U.S. rights to F-18 FAPI-74, a radiotracer for PET scans. GEHC already licensed global rights to Gallium-68 FAPI-46 and non-U.S. rights to F-18 FAPI-74. Sofie operates seven radiopharmacies producing F-18 FAPI-74. The deal's value depends on additional rights, manufacturing earnings, and operational benefits.

insidermonkey.com3 min
SEP 14
$GEHCHighAI 9/10

GE HealthCare Reportedly In Talks To Buy Sofie Biosciences For About $1 Billion

GE HealthCare is reportedly in advanced talks to acquire Sofie Biosciences for around $1 billion, according to the Financial Times. Sofie specializes in radiopharmaceuticals for PET imaging, which could expand GE HealthCare's diagnostics portfolio and create recurring revenue streams. The deal would mark GE HealthCare's second major acquisition since its 2023 separation from General Electric.

pulse2.com3 min
SEP 14
$GEHCHighAI 9/10

GE HealthCare Technologies in talks to buy Sofie Biosciences

GE HealthCare Technologies is in talks to acquire Sofie Biosciences for approximately $1 billion, according to the Financial Times. The deal, which could be announced next week, would be GE HealthCare's second major acquisition since its split from General Electric in 2024. Sofie specializes in radioactive chemicals used in cancer scans, and the acquisition would strengthen GE HealthCare's pharmaceutical diagnostics division.

medicalbuyer.co.in2 min